News for Agent

Daily business news: funding, M&A, launches

Earnings & Results

Paxman Reports 102.9 MSEK Q3 Revenue and Record EBITDA as US Sales Climb 27%

By ·

Key takeaways

  • Paxman reported group revenues of 102.9 MSEK for Q3 2026, up from 86.9 MSEK a year earlier.
  • US revenues rose 27% year over year to 67.8 MSEK, with Paxman IBBM up 106% to 24.9 MSEK.
  • The FDA completed its acceptance review of Paxman's De Novo submission for the Neuropathy System on November 13, 2026.

Paxman reported group revenues of 102.9 MSEK for the third quarter of 2026, up from 86.9 MSEK a year earlier, with an EBITDA margin of 17.5%. The interim report, published by TradingView, also showed US revenues rising 27% year over year to 67.8 MSEK. Paxman is a Swedish-listed medical device company whose scalp cooling systems are used in hospitals and cancer centres to reduce chemotherapy-induced hair loss.

Paxman's US Growth and Group Margins

US revenues reached 67.8 MSEK, or $7.0m, up 27% year over year in local currency. Paxman IBBM contributed 24.9 MSEK ($2.6m), up 106%, and Paxman Self-pay added 21.6 MSEK ($2.2m), up 3%. Dignitana Self-pay brought in 15.8 MSEK ($1.6m), down 8%, while Dignitana IBBM contributed 2.9 MSEK ($0.3m).

Group gross margin was 62%, compared with 62.1% a year earlier, and the adjusted EBITDA margin was 19.5%, down from 20.1%. The adjusted figure excludes costs tied to the acquisition, CIPN and relocation. Net cash at the end of the period was SEK 98 MSEK, against 129.5 MSEK a year earlier, and the group's net result was 7.8 MSEK, with 5.3 MSEK of costs related to the acquisition through goodwill amortisation. Earnings per share were 0.34 SEK, compared with 0.05 SEK.

CEO Richard Paxman commented on the interim report in a presentation with a Q&A session moderated by Maria Karlsson Osipova of DNB Carnegie, available at 9:00 a.m. CET.

Regulatory Steps Behind the Quarter

On July 14, Paxman extended the scope of its UKCA, CE, ISO 13485 and MDSAP certifications to cover its new cryocompression technology for managing chemotherapy-induced peripheral neuropathy (CIPN). On July 16, CMS released proposed CY 2027 OPPS and MPFS rules affecting mechanical scalp cooling, including separate payment for CPT code 97008 under the proposed OPPS rule.

In August, the FDA identified the De Novo process as the appropriate pathway for review of the Limb Cryocompression System for CIPN reduction. On September 28, California enacted Assembly Bill 1682, requiring insurance coverage for FDA-cleared scalp cooling systems from January 1, 2027. In late October, Paxman secured its first UK orders for its Neuropathy System, with four systems to be installed in December 2026, and on November 13 the FDA completed the acceptance review of the De Novo submission and moved it into substantive review, on a target timeline of 150 review days.

Paxman's Reimbursement Record

According to akta.pro company records, CPT Category I codes for mechanised scalp cooling became effective in the United States in January 2026, replacing temporary Category III codes. West Virginia (HB 4089) and Maryland (HB 0393/SB 0272) enacted scalp cooling insurance coverage mandates in April 2026, effective January 2027. The same records show more than 5,000 Paxman systems installed in over 65 markets, with 1,000 systems in the UK covering 98% of private and NHS hospitals.

Earlier Milestones in Paxman's Review

On August 10, 2026, Paxman decided to pursue the De Novo pathway in the United States for its scalp cooling technology instead of the 510(k) process, MarketScreener reported. On August 21, 2026, MarketScreener reported a 40.2% revenue increase to 105 million kronor for the second quarter, the company's highest quarterly revenue and a return to net profit. On November 5, 2026, EIN Presswire reported the launch of the Paxman Neuropathy System for CIPN, the company's first major product expansion beyond scalp cooling.

What Comes Next for Paxman

Paxman said the four UK Neuropathy System orders will be installed in December 2026. California's insurance coverage requirement for FDA-cleared scalp cooling systems takes effect on January 1, 2027. The FDA's target review timeline for the De Novo submission is 150 review days.

Companies in this story

Sources

Machine-readable: Markdown · JSON